Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals
Biotricity (OTCQB:BTCY) has launched a new cardiac monitoring pilot program with a major hospital system serving over 800,000 individuals. This partnership aims to address the growing demand for innovative cardiac monitoring solutions, given that 90% of U.S. adults are at risk of cardiovascular disease and a projected shortage of up to 124,000 physicians in the next 12 years.
Biotricity offers the world's only remote three-channel compact cardiac monitoring device, providing essential health insights and facilitating quicker treatment. The company's solutions can help healthcare professionals increase their revenue fivefold compared to existing options. This is particularly important as 30% of rural hospitals face closure threats, potentially limiting care access for 60 million Americans in those regions.
Biotricity (OTCQB:BTCY) ha avviato un nuovo programma pilota di monitoraggio cardiaco con un importante sistema ospedaliero che serve oltre 800.000 persone. Questa partnership mira a rispondere alla crescente domanda di soluzioni innovative per il monitoraggio cardiaco, considerando che il 90% degli adulti negli Stati Uniti è a rischio di malattie cardiovascolari e si prevede una carenza di fino a 124.000 medici nei prossimi 12 anni.
Biotricity offre l'unico dispositivo di monitoraggio cardiaco compatto a tre canali remoto al mondo, fornendo informazioni fondamentali sulla salute e facilitando trattamenti più rapidi. Le soluzioni dell'azienda possono aiutare i professionisti sanitari a incrementare le loro entrate di cinque volte rispetto alle opzioni esistenti. Questo è particolarmente importante poiché il 30% degli ospedali rurali affronta minacce di chiusura, limitando potenzialmente l'accesso alle cure per 60 milioni di americani in quelle regioni.
Biotricity (OTCQB:BTCY) ha lanzado un nuevo programa piloto de monitoreo cardíaco con un importante sistema hospitalario que atiende a más de 800,000 individuos. Esta asociación tiene como objetivo abordar la creciente demanda de soluciones innovadoras de monitoreo cardíaco, dado que el 90% de los adultos en EE. UU. están en riesgo de enfermedad cardiovascular y se prevé una escasez de hasta 124,000 médicos en los próximos 12 años.
Biotricity ofrece el único dispositivo de monitoreo cardíaco compacto de tres canales remoto en el mundo, proporcionando información esencial sobre la salud y facilitando tratamientos más rápidos. Las soluciones de la empresa pueden ayudar a los profesionales de la salud a incrementar sus ingresos cinco veces en comparación con las opciones existentes. Esto es especialmente importante ya que el 30% de los hospitales rurales enfrenta amenazas de cierre, limitando potencialmente el acceso a la atención para 60 millones de estadounidenses en esas regiones.
Biotricity (OTCQB:BTCY)는 80만 명 이상을 대상으로 하는 주요 병원 시스템과 함께 새로운 심장 모니터링 파일럿 프로그램을 시작했습니다. 이 파트너십은 미국 성인의 90%가 심혈관 질환에 위험이 있다는 점과 향후 12년 동안 최대 12만 4천 명의 의사 부족이 예상되는 가운데 혁신적인 심장 모니터링 솔루션에 대한 증가하는 수요를 해결하는 것을 목표로 하고 있습니다.
Biotricity는 필수 건강 통찰력을 제공하고 더 빠른 치료를 촉진하는 세계 유일의 원격 3채널 소형 심장 모니터링 장치를 제공합니다. 이 회사의 솔루션은 의료 전문가들이 기존 옵션에 비해 수익을 5배 증가시키는 데 도움을 줄 수 있습니다. 이는 농촌 병원의 30%가 폐쇄 위험에 직면해 있다는 점에서 특히 중요하며, 이로 인해 해당 지역의 6천만 미국인이 의료 접근성을 제한받을 수 있습니다.
Biotricity (OTCQB:BTCY) a lancé un nouveau programme pilote de surveillance cardiaque avec un grand système hospitalier desservant plus de 800 000 personnes. Ce partenariat vise à répondre à la demande croissante de solutions innovantes de surveillance cardiaque, étant donné que 90 % des adultes américains sont à risque de maladies cardiovasculaires et qu'une pénurie prévue pouvant atteindre 124 000 médecins au cours des 12 prochaines années est attendue.
Biotricity propose le seul appareil de surveillance cardiaque compact à distance à trois canaux au monde, fournissant des informations essentielles sur la santé et facilitant des traitements plus rapides. Les solutions de la société peuvent aider les professionnels de la santé à augmenter leurs revenus par cinq par rapport aux options existantes. Cela est particulièrement important car 30 % des hôpitaux ruraux font face à des menaces de fermeture, limitant potentiellement l'accès aux soins pour 60 millions d'Américains dans ces régions.
Biotricity (OTCQB:BTCY) hat ein neues Pilotprogramm für die Herzüberwachung mit einem wichtigen Krankenhaussystem gestartet, das über 800.000 Personen versorgt. Diese Partnerschaft zielt darauf ab, der wachsenden Nachfrage nach innovativen Lösungen für die Herzüberwachung gerecht zu werden, da 90% der US-Erwachsenen ein Risiko für Herz-Kreislauf-Erkrankungen haben und in den nächsten 12 Jahren eine voraussichtliche Fachärztemangel von bis zu 124.000 Ärzten besteht.
Biotricity bietet das weltweit einzige kompakte Herzüberwachungsgerät mit drei Kanälen zur Fernüberwachung an, das wesentliche Gesundheitsinformationen bereitstellt und schnellere Behandlungen ermöglicht. Die Lösungen des Unternehmens können Fachleuten des Gesundheitswesens helfen, ihre Einnahmen um das Fünffache zu steigern im Vergleich zu bestehenden Optionen. Dies ist besonders wichtig, da 30% der ländlichen Krankenhäuser von einer Schließungsbedrohung betroffen sind, was den Zugang zur Versorgung für 60 Millionen Amerikaner in diesen Regionen potenziell einschränken könnte.
- Launch of a new cardiac monitoring pilot program with a major hospital system
- Biotricity's solutions can help healthcare professionals increase revenue fivefold
- Offers the world's only remote three-channel compact cardiac monitoring device
- Addresses growing demand for cardiac monitoring solutions due to high cardiovascular disease risk
- None.
REDWOOD CITY, CA / ACCESSWIRE / September 19, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting edge remote monitoring and diagnostic solutions, announces the launch of a new cardiac monitoring pilot program with a top hospital system. With
"This partnership marks a significant step forward in our mission to transform care delivery through advanced remote monitoring technology," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "By collaborating with leaders across medical systems, we are not only enhancing patients' healthcare journeys but also addressing the urgent need for accessible solutions."
Biotricity offers the world's only remote three-channel compact cardiac monitoring device, providing healthcare professionals with essential insights into patients' health, facilitating quicker treatment to optimize outcomes. The company's high-quality data results in decreased patient risk and significantly enhanced clinic workflow efficiency. Moreover, Biotricity empowers healthcare professionals to increase their revenue fivefold compared to existing solutions. This is especially vital as
Integration of Biotricity's advanced cardiac monitoring solutions into major hospitals will poise the company to play a crucial role in reshaping how cardiovascular health and other chronic diseases are managed. For more information about Biotricity and its innovative healthcare solutions, please visit Biotricity.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Biotricity Investor Relations
Investors@biotricity.com
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
FAQ
What is the new pilot program announced by Biotricity (BTCY)?
How can Biotricity's (BTCY) solutions impact healthcare professionals' revenue?
What unique product does Biotricity (BTCY) offer in cardiac monitoring?
What percentage of U.S. adults are at risk of cardiovascular disease according to Biotricity's (BTCY) press release?
